KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) Research & Development (2016 - 2025)

Thermo Fisher Scientific's Research & Development history spans 17 years, with the latest figure at $356.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 4.81% year-over-year to $356.0 million, compared with a TTM value of $1.4 billion through Dec 2025, changed 0.43%, and an annual FY2025 reading of $1.4 billion, up 0.5% over the prior year.
  • Research & Development for Q4 2025 was $356.0 million at Thermo Fisher Scientific, up from $346.0 million in the prior quarter.
  • The five-year high for Research & Development was $392.0 million in Q4 2021, with the low at $319.0 million in Q3 2023.
  • Average Research & Development over 5 years is $350.0 million, with a median of $346.0 million recorded in 2023.
  • Year-over-year, Research & Development surged 30.61% in 2021 and then decreased 16.37% in 2023.
  • Tracing TMO's Research & Development over 5 years: stood at $392.0 million in 2021, then fell by 0.26% to $391.0 million in 2022, then decreased by 16.37% to $327.0 million in 2023, then grew by 14.37% to $374.0 million in 2024, then fell by 4.81% to $356.0 million in 2025.
  • Per Business Quant, the three most recent readings for TMO's Research & Development are $356.0 million (Q4 2025), $346.0 million (Q3 2025), and $352.0 million (Q2 2025).